Michael T Lu, Heather Ribaudo, Borek Foldyna, Markella V Zanni, Thomas Mayrhofer, Julia Karady, Jana Taron, Kathleen V Fitch, Sara McCallum, Tricia H Burdo, Kayla Paradis, Sandeep S Hedgire, Nandini M Meyersohn, Christopher DeFilippi, Carlos D Malvestutto, Audra Sturniolo, Marissa Diggs, Sue Siminski, Gerald S Bloomfield, Beverly Alston-Smith, Patrice Desvigne-Nickens, Edgar T Overton, Judith S Currier, Judith A Aberg, Carl J Fichtenbaum, Udo Hoffmann, Pamela S Douglas, Steven K Grinspoon
IMPORTANCE: Cardiovascular disease (CVD) is increased in people with HIV (PWH) and is characterized by premature noncalcified coronary plaque. In the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), pitavastatin reduced major adverse cardiovascular events (MACE) by 35% over a median of 5.1 years. OBJECTIVE: To investigate the effects of pitavastatin on noncalcified coronary artery plaque by coronary computed tomography angiography (CTA) and on inflammatory biomarkers as potential mechanisms for MACE prevention...
February 21, 2024: JAMA Cardiology